Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis
Quantum BioPharma advances LUCID-MS for multiple sclerosis, completing Phase 1 trials and submitting an IND to FDA. Learn about this novel therapy targeting myelin repair.
This news matters because multiple sclerosis affects millions worldwide, and current treatments often fail to prevent long-term disability. LUCID-MS targets the root cause—myelin damage—rather than just inflammation, potentially offering a disease-modifying therapy that could preserve mobility and improve quality of life for MS patients. The progression to FDA submission signals a step closer to a new treatment option.
